Is TP53 Mutated AML the Same Disease as TP53 Mutated MDS?

被引：0
|
作者：
Valk, Peter J. M. [1 ]
机构：
[1] Univ Med Ctr Rotterdam, Erasmus MC Canc Inst, Dept Hematol, Rotterdam, Netherlands
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2022年 / 22卷
关键词：
AML; MDS-EB; TP53; mutation; outcome; ALLELE FREQUENCY; MUTATIONS; OUTCOMES;
D O I：
10.1016/S2152-2650(22)00640-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
下载
收藏
页码：S3 / S5
页数：3
相关论文
共 50 条
  • [21] TP53 Mutated MDS Patients Respond Equally to Hypomethylating Agents but Have Significantly Shorter Response Duration Compared to Patients with Wild Type TP53
    Takahashi, Koichi
    Kantarjian, Hagop M.
    Patel, Keyur
    Bueso-Ramos, Carlos E.
    Kadia, Tapan
    Jabbour, Elias
    DiNardo, Courtney
    Daver, Naval
    Pierce, Sherry
    Futreal, Andrew
    Garcia-Manero, Guillermo
    BLOOD, 2015, 126 (23)
  • [22] Genomic Context and TP53 Allele Frequency Define Prognostic Subgroups and Response Outcomes in TP53 Mutated Myelodysplastic Syndromes
    Montalban-Bravo, Guillermo
    Kanagal-Shamanna, Rashmi
    Benton, Christopher B.
    Class, Caleb
    Chien, Kelly S.
    Sasaki, Koji
    Naqvi, Kiran
    Alvarado, Yesid
    Kadia, Tapan M.
    Ravandi, Farhad
    Cortes, Jorge E.
    Daver, Naval G.
    Takahashi, Koichi
    DiNardo, Courtney D.
    Jabbour, Elias
    Borthakur, Gautam M.
    Pemmaraju, Naveen
    Konopleva, Marina Y.
    Pierce, Sherry A.
    Bueso-Ramos, Carlos E.
    Andreeff, Michael
    Patel, Keyur P.
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    BLOOD, 2019, 134
  • [23] Comparative Assessment of p53 Immunohistochemistry and TP53 Molecular Analysis for Prediction in Diagnosis of TP53 Mutated Acute Myeloid Leukemia
    Matsumoto, Nana
    Wilton, Katelynn
    Pinkus, Geraldine
    Lovitch, Scott
    LABORATORY INVESTIGATION, 2023, 103 (03) : S1192 - S1193
  • [24] The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
    Leroy, Bernard
    Fournier, Jean Louis
    Ishioka, Chikashi
    Monti, Paola
    Inga, Alberto
    Fronza, Gilberto
    Soussi, Thierry
    NUCLEIC ACIDS RESEARCH, 2013, 41 (D1) : D962 - D969
  • [25] Predicted Functional Consequences of TP53 Alterations and Prognosis in TP53-Mutated Mantle Cell Lymphoma
    Uppal, Manik
    Joffe, Erel
    Bantilan, Kurt S.
    Salles, Gilles
    Soumerai, Jacob
    Zelenetz, Andrew D.
    Kumar, Anita
    BLOOD, 2023, 142
  • [26] TP53 Combined Phenotype Score Is Associated with the Clinical Outcome of TP53-Mutated Myelodysplastic Syndromes
    Yabe, Mariko
    Omarbekova, Aidana Z.
    Hsu, Meier
    May, Hannah
    Arcila, Maria E.
    Liu, Ying
    Dogan, Ahmet
    Brunner, Andrew M.
    Nardi, Valentina
    Hasserjian, Robert P.
    Klimek, Virginia M.
    CANCERS, 2021, 13 (21)
  • [27] The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases
    A Stengel
    W Kern
    T Haferlach
    M Meggendorfer
    A Fasan
    C Haferlach
    Leukemia, 2017, 31 : 705 - 711
  • [28] The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases
    Stengel, A.
    Kern, W.
    Haferlach, T.
    Meggendorfer, M.
    Fasan, A.
    Haferlach, C.
    LEUKEMIA, 2017, 31 (03) : 705 - 711
  • [29] Decitabine in TP53-Mutated AML
    Montalban-Bravo, Guillermo
    Takahashi, Koichi
    Garcia-Manero, Guillermo
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (08): : 796 - 797
  • [30] Halofuginone Exerts Antileukemic Effects in TP53 Mutated Cell Lines
    Candido, Larissa
    Thome, Carol Hassibe
    Silva, Cleide Lucia de Araujo
    Moreno, Daniel Antunes
    Weinhauser, Isabel
    de Almeida, Luciana Yamamoto
    Bonaldo, Camila
    Rego, Eduardo Magalhaes
    Nagler, Arnon
    Pereira-Martins, Diego Antonio
    BLOOD, 2017, 130
12345